Aging is a significant risk factor for breast cancer, with nearly 50% of all cases diagnosed in individuals aged 65 and older. Alarmingly, about 20% of diagnoses occur in women aged 75 and above. Despite this prevalence, older patients are often underrepresented in clinical trials. For instance, one analysis revealed that just 9% of participants in breast cancer studies were 65 or older. This exclusion results in a lack of comprehensive guidelines for treating this demographic, making personalized care essential.
Dr. Neil Carleton, a cancer biologist and first-year resident at Brigham and Women’s Hospital, underscores the need for tailored treatments for older women. He notes that breast tumors in older patients often behave differently due to variations in hormone levels and the impact of inflammation. Historically, treatments have followed an ‘age-agnostic’ approach, which may not serve this patient group adequately.
As mentioned, age considerably influences breast cancer behavior and response to treatment. Carleton advocates for a paradigm shift aimed at individualizing treatments. Understanding that older women often have a different biological response allows healthcare providers to offer treatments tailored to this unique population, potentially improving outcomes by minimizing unnecessary interventions.
Having dedicated his research efforts towards better understanding the needs of older patients, Carleton's work highlights that many older women may be subjected to overtreatment, particularly in procedures like sentinel lymph node biopsies. Despite guidelines suggesting that biopsies should be avoided in women aged 70 and over with early-stage cancer, data showed that approximately 65% were still undergoing this surgery.
To tackle this issue, Carleton and his colleagues developed a nudge within electronic health records designed to remind clinicians to reconsider unnecessary biopsies when treating qualifying patients. This innovative approach saw a significant decrease in biopsy rates, almost halving them within a year after implementation across eight clinics, reinforcing the effectiveness of integrating behavioral economics in healthcare decision-making.
Carleton's lab work explored a baffling question: how do breast tumors in older women, many of whom have lower estrogen levels due to aging, continue to thrive? His investigations revealed that these tumors could produce their own estrogen through an enzyme that converts estrone to estradiol, the more potent form of estrogen. Identifying this enzyme opens new avenues for tailored therapies.
The findings from Carleton's research highlight the potential for targeted therapies aimed at inhibiting this enzyme, which could reduce side effects typically associated with current treatments like aromatase inhibitors. Such drugs often lead to patient discomfort, causing many to discontinue treatment prematurely.
Interestingly, Carleton also observed that some patients over 70 chose to avoid surgery entirely, relying only on endocrine therapy to control their cancer. Remarkably, only 3% of those patients died from breast cancer within six years, emphasizing that less invasive approaches can be both effective and safer.
To monitor these patients more effectively, Carleton proposed utilizing circulating tumor DNA (ctDNA) to assess disease progression. This method requires only a blood sample, allowing for a less invasive approach compared to traditional monitoring techniques. Early trials indicated that patients with detectable ctDNA were significantly more likely to experience disease progression.
Currently, as Carleton balances his residency and research, he envisions a future where breast cancer can be managed as a chronic disease rather than a life-threatening one. His commitment to refining cancer care for older women speaks volumes about the necessity of personalized, evidence-based treatment strategies aimed at improving quality of life for this vulnerable population. By continuously adapting to the specific needs of older patients, the aim is to shift the landscape of breast cancer treatment for older women into a more effective and compassionate direction.